Hospital
West Kendall Baptist Hospital INC
West Kendall Baptist Hospital INC was paid $17.97M by Medicaid between Jan 2018 and Dec 2024, across 190 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoWEST KENDALL BAPTIST HOSPITAL INC
MIAMI, FL 33196
MIAMI, FL 33196
33aNPI1417279936assigned 02/25/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.97M
24GClaims634,001
24DCodes billed190
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#22 of 163
Median peer was paid$4.77M
This provider vs. median3.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 45,628 | $592K | |
| 2019 | 112,040 | $2.07M | |
| 2020 | 79,386 | $1.61M | |
| 2021 | 128,645 | $3.52M | |
| 2022 | 139,897 | $4.89M | |
| 2023 | 82,422 | $3.60M | |
| 2024incomplete | 45,983 | $1.69M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 44,702 | 40,784 | $4.50M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 46,830 | 40,245 | $4.14M |
| 36415 | Collection of venous blood by venipuncture | 7.9% | 42,488 | 30,706 | $1.41M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.7% | 16,900 | 14,246 | $1.21M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.9% | 5,635 | 5,131 | $1.06M |
| 70450 | Computed tomography, head or brain; without contrast material | 5.6% | 7,952 | 6,535 | $1.00M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.5% | 4,956 | 4,220 | $980K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 4,587 | 4,316 | $339K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 12,462 | 9,657 | $263K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.4% | 6,092 | 5,527 | $251K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.2% | 1,202 | 1,075 | $216K |
| G0378 | Hospital observation service, per hour | <1% | 6,307 | 3,594 | $135K |
178 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 8,203 | $135K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,321 | $127K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 894 | $124K |
| 80076 | <1% | 20,258 | $121K | |
| 86900 | <1% | 2,808 | $95K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,082 | $88K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,783 | $79K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,130 | $72K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 37,931 | $68K |
| 72131 | <1% | 844 | $66K | |
| 87081 | <1% | 6,891 | $62K | |
| 86850 | <1% | 2,424 | $54K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,273 | $52K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,586 | $52K |
| 86901 | <1% | 2,696 | $48K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,424 | $46K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,128 | $45K |
| 10060 | <1% | 229 | $45K | |
| 70491 | <1% | 134 | $43K | |
| 87430 | <1% | 6,482 | $42K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,273 | $41K |
| 71250 | <1% | 1,142 | $41K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,552 | $38K |
| 81003 | <1% | 6,487 | $35K | |
| 87088 | <1% | 6,742 | $33K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,125 | $30K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,401 | $29K |
| 73630 | <1% | 1,381 | $27K | |
| 73610 | <1% | 1,159 | $26K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,495 | $23K |
| 73562 | <1% | 1,565 | $23K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 5,168 | $20K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 44,190 | $20K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,149 | $20K |
| 81001 | <1% | 12,958 | $19K | |
| 73130 | <1% | 990 | $18K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,714 | $17K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,342 | $17K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,143 | $17K |
| 73030 | <1% | 913 | $17K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 749 | $16K |
| 76830 | Ultrasound, transvaginal | <1% | 1,453 | $16K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,073 | $15K |
| A9270 | Non-covered item or service | <1% | 5,701 | $15K |
| 74018 | <1% | 1,068 | $14K | |
| 76801 | <1% | 1,175 | $14K | |
| 87040 | <1% | 2,474 | $13K | |
| 12011 | <1% | 209 | $13K | |
| 82962 | <1% | 2,681 | $13K | |
| 81025 | <1% | 2,251 | $13K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 91 | $12K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,282 | $11K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,968 | $11K |
| 73110 | <1% | 521 | $11K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 164 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,053 | $10K |
| 87486 | <1% | 1,081 | $10K | |
| 84520 | <1% | 4,298 | $10K | |
| 70486 | <1% | 256 | $10K | |
| 82947 | <1% | 4,115 | $10K | |
| 84132 | <1% | 2,780 | $9K | |
| 82565 | <1% | 4,295 | $9K | |
| 84295 | <1% | 2,772 | $9K | |
| 82435 | <1% | 2,777 | $9K | |
| 12001 | <1% | 154 | $9K | |
| 84145 | <1% | 2,281 | $8K | |
| 82374 | <1% | 2,741 | $8K | |
| 93970 | <1% | 589 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,372 | $7K |
| 80051 | <1% | 1,518 | $7K | |
| 87077 | <1% | 2,615 | $6K | |
| 76775 | <1% | 181 | $6K | |
| 87581 | <1% | 702 | $6K | |
| 97161 | <1% | 305 | $6K | |
| 83880 | <1% | 2,020 | $6K | |
| 87428 | <1% | 3,073 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,225 | $6K |
| 83735 | <1% | 6,663 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,411 | $5K |
| 83605 | <1% | 6,419 | $5K | |
| 87186 | <1% | 2,235 | $5K | |
| 84484 | <1% | 9,611 | $5K | |
| 85610 | <1% | 7,828 | $5K | |
| 83690 | <1% | 12,382 | $5K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 388 | $4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,578 | $4K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 87 | $4K |
| 93971 | <1% | 1,074 | $4K | |
| 85730 | <1% | 7,065 | $4K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,023 | $3K |
| 72100 | <1% | 431 | $3K | |
| 73080 | <1% | 237 | $3K | |
| 87205 | <1% | 1,115 | $3K | |
| 87807 | <1% | 351 | $3K | |
| 82310 | <1% | 674 | $3K | |
| 85379 | <1% | 2,129 | $3K | |
| 80061 | Lipid panel | <1% | 950 | $3K |
| 84703 | <1% | 7,326 | $2K | |
| 85027 | <1% | 2,333 | $2K | |
| 96376 | <1% | 2,028 | $2K | |
| 97165 | <1% | 454 | $2K | |
| 73090 | <1% | 76 | $2K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 79 | $2K |
| 82805 | <1% | 365 | $2K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 80 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,245 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 692 | $2K |
| 97162 | <1% | 92 | $1K | |
| 93976 | <1% | 257 | $1K | |
| 87070 | <1% | 509 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,990 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 235 | $1K |
| 82376 | <1% | 332 | $948.24 | |
| 84702 | <1% | 1,736 | $924.75 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 326 | $913.75 |
| 72192 | <1% | 13 | $829.97 | |
| 74021 | <1% | 63 | $556.67 | |
| 96367 | <1% | 65 | $539.97 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 16 | $529.15 |
| 87210 | <1% | 384 | $509.21 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 21 | $502.89 |
| 80053 | Comprehensive metabolic panel | <1% | 1,532 | $483.76 |
| 90715 | <1% | 129 | $464.28 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 499 | $380.78 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 944 | $378.02 |
| 71101 | <1% | 53 | $362.11 | |
| 87046 | <1% | 73 | $353.78 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 809 | $332.54 |
| 76870 | <1% | 13 | $329.95 | |
| 84100 | <1% | 665 | $245.67 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 145 | $229.25 |
| 86140 | <1% | 1,804 | $228.67 | |
| 73590 | <1% | 177 | $220.56 | |
| J3490 | Unclassified drugs | <1% | 517 | $168.04 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 390 | $134.01 |
| 87899 | <1% | 73 | $125.24 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 107 | $118.61 |
| 82150 | <1% | 406 | $114.19 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 872 | $96.24 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 57 | $93.12 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 41 | $85.48 |
| 82550 | <1% | 860 | $59.10 | |
| 82077 | <1% | 136 | $58.36 | |
| 83045 | <1% | 308 | $27.82 | |
| 86592 | <1% | 137 | $22.33 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 145 | $19.68 |
| 82607 | <1% | 127 | $16.75 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 38 | $8.15 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 38 | $8.15 |
| 87045 | <1% | 39 | $5.18 | |
| 82040 | <1% | 24 | $3.33 | |
| 85384 | <1% | 12 | $2.50 | |
| 85652 | <1% | 614 | $1.76 | |
| 84075 | <1% | 12 | $1.66 | |
| 84450 | <1% | 13 | $1.66 | |
| 84460 | <1% | 13 | $1.66 | |
| 84155 | <1% | 12 | $1.66 | |
| 83615 | <1% | 19 | $1.48 | |
| J2704 | Injection, propofol, 10 mg | 0% | 32 | $0.00 |
| 86308 | 0% | 374 | $0.00 | |
| 87147 | 0% | 53 | $0.00 | |
| 73502 | 0% | 91 | $0.00 | |
| 82728 | 0% | 67 | $0.00 | |
| 73060 | 0% | 15 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 19 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 14 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 17 | $0.00 |
| 80143 | 0% | 60 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 71 | $0.00 |
| 80179 | 0% | 44 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 26 | $0.00 |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 0% | 18 | $0.00 |
| 94664 | 0% | 123 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 44 | $0.00 |
| 84439 | 0% | 40 | $0.00 | |
| 92610 | 0% | 18 | $0.00 | |
| 82140 | 0% | 51 | $0.00 | |
| 84550 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOUE, LOURDES (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Doctors Hospital INC | Coral Gables, FL | $1.25M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.